Accordingly, MYC is strongly expressed in both KCL-22R and CML-T1R clones and CML-resistant primary cells, as described previously (40), and its binding was enriched in the LIG1 transcription start site (TSS) at the time of mutation acquisition. This evidence concerns the gene LIG1 and chronic myelogenous leukemia, BCR-ABL1 positive.